We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy and Safety of Tripterygium Wilfordii in Patients With Rheumatoid Arthritis (TRIFRA)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01613079
First Posted: June 6, 2012
Last Update Posted: August 5, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Xuan Zhang, Peking Union Medical College Hospital
  Purpose
Evaluation of oral T2 (chloroform/methanol extract of Tripterygium wilfordii Hook F) in the treatment of RA patients with clinical efficacy and safety.Open-labeled, randomized, prospective multi-center clinical trial. Observation period of 24 weeks.

Condition Intervention Phase
Arthritis, Rheumatoid Drug: Tripterygium wilfordii Hook F Drug: Methotrexate Phase 2 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Evaluation of Oral T2 (Chloroform/Methanol Extract of Tripterygium Wilfordii Hook F) in the Treatment of RA Patients With Clinical Efficacy and Safety.

Resource links provided by NLM:


Further study details as provided by Xuan Zhang, Peking Union Medical College Hospital:

Primary Outcome Measures:
  • ACR50 [ Time Frame: 24 weeks. ]
    The proportion of patients achieving ACR50.


Secondary Outcome Measures:
  • Radiology outcome [ Time Frame: 24 weeks ]
    The change in X-Ray from baseline to week 24.

  • DAS28 [ Time Frame: 24 weeks ]
    The change in DAS score from baseline to week 24.

  • ACR20/70 [ Time Frame: 24 weeks ]
    The proportion of patients achieving ACR20 & ACR70.


Enrollment: 201
Study Start Date: May 2012
Study Completion Date: June 2013
Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Methotrexate
Patients were treated with methotrexate alone.
Drug: Methotrexate
Oral methotrexate 7.5-12.5mg per week for 24 weeks. The starting dose was 7.5mg per week, then increased to 12.5mg(max 0.3mg/Kg) per week in 4 weeks. Folic acid at the dose of 10mg per week were applied to all patients.
Experimental: T2
Patients were treated with oral T2 (chloroform/methanol extract of Tripterygium wilfordii Hook F).
Drug: Tripterygium wilfordii Hook F
Oral T2(Tripterygium wilfordii Hook F) 20mg thrice daily for 24 weeks.
Experimental: MTX+T2
The patients were treated with methotrexate and T2.
Drug: Tripterygium wilfordii Hook F
Oral T2(Tripterygium wilfordii Hook F) 20mg thrice daily for 24 weeks.
Drug: Methotrexate
Oral methotrexate 7.5-12.5mg per week for 24 weeks. The starting dose was 7.5mg per week, then increased to 12.5mg(max 0.3mg/Kg) per week in 4 weeks. Folic acid at the dose of 10mg per week were applied to all patients.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age 18-65 years with informed consent
  • Diagnosed with rheumatoid arthritis as determined by meeting the 2010 ACR/EULAR classification criteria and has had rheumatoid arthritis for at least 6 weeks
  • Swollen joint (SJC)≥3 and tender joint count(TJC)≥5
  • ESR >28 mm/hr or C-reactive protein > 20 mg/L

Exclusion Criteria:

  • Pregnant, lactating or further fertility requirements
  • Previous treated with methotrexate or biologic DMARD.
  • Active or chronic infection, including HIV, HCV, HBV, tuberculosis
  • Patient with cancer
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01613079


Locations
China, Beijing
Deptment of Rheumatology, Peking Union Medical College Hospital
Beijing, Beijing, China, 100032
Sponsors and Collaborators
Peking Union Medical College Hospital
Investigators
Principal Investigator: Xuan Zhang, MD Peking Union Medical College Hospital
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Xuan Zhang, Professor, Peking Union Medical College Hospital
ClinicalTrials.gov Identifier: NCT01613079     History of Changes
Other Study ID Numbers: TRIFRA
First Submitted: June 4, 2012
First Posted: June 6, 2012
Last Update Posted: August 5, 2013
Last Verified: August 2013

Keywords provided by Xuan Zhang, Peking Union Medical College Hospital:
Rheumatoid Arthritis
Methotrexate
Tripterygium

Additional relevant MeSH terms:
Arthritis
Arthritis, Rheumatoid
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Methotrexate
Abortifacient Agents, Nonsteroidal
Abortifacient Agents
Reproductive Control Agents
Physiological Effects of Drugs
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Dermatologic Agents
Enzyme Inhibitors
Folic Acid Antagonists
Immunosuppressive Agents
Immunologic Factors
Antirheumatic Agents
Nucleic Acid Synthesis Inhibitors